8-KAcquisitions & DispositionsExhibits & Filings

3M CO 8-K Report, Acquisition Completed (Apr 4, 2024)

Filed April 4, 2024For Securities:MMM

Summary

3M Company (MMM) has officially completed the separation of its health care business, now named Solventum Corporation (SOLV), through a pro rata stock distribution. This significant event, effective April 1, 2024, means 3M stockholders received shares of Solventum as a separate, independent public company listed on the NYSE under the ticker "SOLV". This strategic move is designed to allow both 3M and Solventum to pursue distinct growth strategies and enhance shareholder value by focusing on their respective core competencies. The filing also provides investors with access to important pro forma financial information. These unaudited financial statements offer a view of 3M's financial position and performance as if the separation had occurred at earlier dates, enabling a clearer understanding of the ongoing business's standalone financial profile and the impact of this strategic divestiture.

Key Highlights

  • 13M completed the separation of its health care business on April 1, 2024.
  • 2The separated health care business now operates as an independent public company named Solventum Corporation (SOLV).
  • 3Solventum's common stock began trading on the New York Stock Exchange (NYSE) under the ticker symbol "SOLV".
  • 43M stockholders received 80.1% of Solventum's shares through a pro rata distribution.
  • 5Shareholders of record on March 18, 2024, received one share of Solventum for every four shares of 3M held.
  • 6Cash will be provided for fractional Solventum shares.
  • 7Unaudited pro forma financial statements reflecting the separation are attached, providing insight into the standalone financial health of both entities.

Frequently Asked Questions

This 8-K filing announces the completion of 3M's separation of its health care business, which is now an independent company called Solventum Corporation (SOLV). It confirms the effective date of the separation and distribution, and provides access to pro forma financial information.

Shareholders of record as of March 18, 2024, received one share of Solventum common stock for every four shares of 3M common stock they held. This was a pro rata distribution of 80.1% of Solventum's shares.

The separation allows 3M to focus more strategically on its remaining businesses (Safety & Industrial, Transportation & Electronics, and Consumer) and pursue growth opportunities within those segments. It also enables Solventum to operate as an independent entity focused solely on the health care market.

This filing includes unaudited pro forma condensed consolidated financial statements for 3M that reflect the separation. Investors should also refer to Solventum's own SEC filings for detailed financial information about the new company.